Japanese drugmaker Shionogi announced last week that the US government has ordered $37 million worth of the antibiotic ceferidocol to support national preparedness.
The Biomedical Advanced Research and Development Authority’s (BARDA’s) Project BioShield exercised the $36.9 million procurement option on the antibiotic as a critical countermeasure against difficult-to-treat gram-negative bacterial infections and pathogens that could pose a biosecurity threat.
Marketed under the brand name Fetroja, cefiderocol is a siderophore cephalosporin antibiotic with a novel method of penetrating the tough outer membrane of gram-negative bacteria and an ability to overcome resistance mechanisms used by bacteria to evade antibiotics.
Potential treatment for biothreats
Cefiderocol was approved by the US Food and Drug Administration for treating complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It’s since become a valued option for difficult-to-treat multidrug-resistant infections.
The order is the first of several procurement options under a contract signed in April between BARDA and Shionogi that’s worth up to $482 million. The contract includes plans to develop a US manufacturing site for cefiderocol, expand its use in children with pneumonia, and study its potential to treat infections caused by Yersinia pestis, the bacterium that causes plague, and Burkholderia pseudomallei, which causes melioidosis.
Both pathogens occur naturally in certain parts of the world and have the potential to be used as weapons in a biological attack.